Not available at the moment magazine essay contests Lilly’s 2013 profit upturn will be short-lived, however. Investors expect earnings to take a tumble of perhaps 25 percent in 2014, as generic versions of Cymbalta and osteoporosis drug Evista flood the market.
Blair
